亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Anlotinib plus docetaxel vs. docetaxel alone for advanced non-small-cell lung cancer patients who failed first-line treatment: A multicenter, randomized phase II trial

多西紫杉醇 医学 内科学 肺癌 肿瘤科 随机对照试验 多中心试验 多中心研究 化疗
作者
Xingxiang Pu,Zemin Xiao,Jia Li,Zhijun Wu,Zhongxia Ma,Jie Weng,Maoliang Xiao,Yanhua Chen,Yongqing Cao,Peiguo Cao,Qianzhi Wang,Xu Yan,Kang Li,Bolin Chen,Xu Fang,Liyu Liu,Yi Kong,Hui Zhang,Huaxin Duan,Lin Wu
出处
期刊:Lung Cancer [Elsevier BV]
卷期号:191: 107538-107538 被引量:4
标识
DOI:10.1016/j.lungcan.2024.107538
摘要

ObjectivesGiven the modest efficacy of docetaxel in advanced non-small cell lung cancer (NSCLC), this study assesses the therapeutic potential and safety profile of anlotinib in combination with docetaxel compared to docetaxel monotherapy as a second-line therapy for patients with advanced NSCLC.Materials and MethodsIn this phase II study, patients with advanced NSCLC experiencing failure with first-line platinum-based regimens were randomized in a 1:1 ratio to receive either anlotinib plus docetaxel or docetaxel alone. Primary endpoint was progression-free survival (PFS), with overall survival (OS), objective response rate (ORR), disease control rate (DCR), and safety as secondary endpoints.ResultsA total of 83 patients were randomized. The combination of anlotinib and docetaxel significantly extended median PFS to 4.4 months compared to 1.6 months for docetaxel alone (hazard ratio [HR] = 0.38, 95 % confidence interval [CI]: 0.23–0.63, P = 0.0002), and also demonstrated superior ORR (32.5 % vs. 9.3 %, P = 0.0089) and DCR (87.5 % vs. 53.5 %, P = 0.0007). Median OS was observed at 12.0 months in the combination group versus 10.9 months in the monotherapy group (HR = 0.82, 95 % CI: 0.47–1.43, P = 0.4803). For patients previously treated with immunotherapy, the median PFS was notably longer at 7.8 versus 1.7 months (HR = 0.22, 95 % CI: 0.09–0.51, P = 0.0290). The incidence of grade ≥ 3 treatment-related adverse events, predominantly leukopenia (15.0 % vs. 7.0 %) and neutropenia (10.0 % vs. 5.0 %), was manageable across both groups.ConclusionAnlotinib plus docetaxel offers a viable therapeutic alternative for patients with advanced NSCLC who failed first-line platinum-based treatments.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
TS6539完成签到,获得积分10
4秒前
bababiba完成签到,获得积分10
7秒前
10秒前
CipherSage应助archer01采纳,获得10
19秒前
量子星尘发布了新的文献求助10
35秒前
45秒前
1分钟前
量子星尘发布了新的文献求助10
1分钟前
1分钟前
2分钟前
2分钟前
2分钟前
星辰大海应助科研通管家采纳,获得10
2分钟前
3分钟前
量子星尘发布了新的文献求助10
3分钟前
月儿完成签到 ,获得积分10
3分钟前
冬去春来完成签到 ,获得积分10
3分钟前
3分钟前
小江完成签到,获得积分10
3分钟前
gszy1975完成签到,获得积分10
3分钟前
3分钟前
3分钟前
Chaos完成签到 ,获得积分10
4分钟前
光合作用完成签到,获得积分10
4分钟前
4分钟前
4分钟前
4分钟前
八个猪宝贝完成签到,获得积分10
4分钟前
量子星尘发布了新的文献求助10
5分钟前
lameliu完成签到,获得积分10
5分钟前
5分钟前
香蕉觅云应助Viiigo采纳,获得10
5分钟前
5分钟前
量子星尘发布了新的文献求助10
6分钟前
6分钟前
老石完成签到 ,获得积分10
6分钟前
chichqq发布了新的文献求助30
6分钟前
6分钟前
evil发布了新的文献求助10
6分钟前
7分钟前
高分求助中
The Mother of All Tableaux Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 2400
Ophthalmic Equipment Market by Devices(surgical: vitreorentinal,IOLs,OVDs,contact lens,RGP lens,backflush,diagnostic&monitoring:OCT,actorefractor,keratometer,tonometer,ophthalmoscpe,OVD), End User,Buying Criteria-Global Forecast to2029 2000
Optimal Transport: A Comprehensive Introduction to Modeling, Analysis, Simulation, Applications 800
Official Methods of Analysis of AOAC INTERNATIONAL 600
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 588
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
T/CIET 1202-2025 可吸收再生氧化纤维素止血材料 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3957061
求助须知:如何正确求助?哪些是违规求助? 3503084
关于积分的说明 11111255
捐赠科研通 3234121
什么是DOI,文献DOI怎么找? 1787751
邀请新用户注册赠送积分活动 870772
科研通“疑难数据库(出版商)”最低求助积分说明 802264